Urinary System Carcinoma — Trials

Urinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 670
Recruiting: 353
Ph III recruiting: 41
Growth YoY: +12.6%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (391)

clinicaltrialsPublishedShowing 101–112 of 112 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06528483	Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer(preSAVE)	not yet recruiting	Phase 2	63	Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER	1	Jul 30, 2024	clinicaltrials
NCT06523049	Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy	not yet recruiting	Phase 2	67	Hao ZengOTHER	1